Press Releases

SHL Medical, a global leader in the design, development, and manufacturing of advanced self-injection solutions, has officially inaugurated its new state-of-the-art manufacturing facility in North Charleston, South Carolina. This strategic expansion marks a significant milestone in the Swiss-based company’s global growth, reinforcing its commitment to meeting the increasing worldwide demand for autoinjectors, most notably used in the cardiometabolic sector. The new facility wi

AKAGERA Medicines, Inc. is a biotech company focused on the discovery and development of novel lipid nanoparticle formulations of antibacterial drugs and mRNA vaccines to treat tuberculosis, avian flu, RSV and other infectious diseases. The company announced today that it completed the first cohort in its first-in-human phase 1 SAD/MAD study of AKG-100, which is an oxazolidinone class of antibiotic for treatment of pulmonary tuberculosis (TB). AKAGERA Medicines is substantially supp

Vertex Pharmaceuticals Incorporated today announced several updates on the Company’s type 1 diabetes (T1D) portfolio. VX-264 Update Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 (cells + device) study and the planned analysis at Day 90 for Part B. In Part B of the study, participants received the full dose of the investigational fully differentiated pancreatic islet cell therapy encapsulated in a proprietary immu

Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled generative AI engine. Building on successes in epitranscriptomics, Aqemia aims to develop novel small-molecule drugs against this emerging and promising class of therapeutic targets. In parallel with advancing RNA-focused initiatives, the company continues to drive innovation in its broader pipeline, including protein-targeting programs. Aqemia has secured a $7.4 mi

Novagen, a leading full-service biotech contract research organization (CRO), today announced that affiliates of Singapore’s GIC and Temasek have signed binding definitive agreements to acquire a significant equity stake in the company, with additional capital to be used to accelerate Novagen’s global growth. Existing investor TPG will reinvest through its TPG Asia Fund. Headquartered in Singapore and with more than 30 offices around the world, Novotech is one of the wor

Coya Therapeutics, Inc. a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer’s disease (AD), Alireza Faridar, M.D. from Houston Methodist Hospital, will be presenting previously announced progress to date at the ADPD 2025 conference in Vienna. The presentation, titled, “A Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients wi

AptarGroup, Inc. a global leader in drug and consumer product dosing, dispensing and protection technologies, has been named one of Barron’s 100 Most Sustainable U.S. Companies for the seventh consecutive year and is ranked number 26 out of the top 100 companies for 2025. Graphic: Aptar Named One of Barron’s 100 Most Sustainable U.S. Companies for the Seventh Consecutive Year. Used with permission. ©2025 Dow Jones & Company, Inc. “Being recognize

Jazz Pharmaceuticals plc today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 9, 2025, at 9:45 a.m. PT / 12:45 p.m. ET / 5:45 p.m. IST. An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on

Apnimed, Inc., a pharmaceutical company focused on discovering, developing, and commercializing first-in-class oral therapies for the neuromuscular dysfunction associated with obstructive sleep apnea (OSA) and other sleep-related breathing diseases, today announced that Larry Miller, M.D., Chief Executive Officer, and Ramzi Benamar, Chief Financial Officer, will be presenting at the 24th Annual Needham Virtual Healthcare Conference, which takes place April 7-10, 2025. Detail

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, today highlighted the significance of the U.S. Food and Drug Administration’s (FDA) approval of Qfitlia™ (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood clotting, with the goal of promoting thrombin generation to rebalance hemostasis and prevent bleeds. Qfitlia is indicated in the U.S. for